THE DPI ARE STILL VACCINATING YOUNG FOALS WHEN IT DOES NOT OFFER THEM ANY IMMUNITY ???????
Trying to sort out confusion?
ProteqFLU-Te
Application number
EMEA/V/C/074
Marketing authorisation holder
MERIAL, France
Name of the product
ProteqFLU-TeActive substances
Live recombinant canarypox viruses expressing the haemagglutin HA gene from the equine influenza virus strains A/equi-2/Kentucky/94 (USA representative) and A/equi-2/Newmarket/293 (European representative) + tetanus toxoid.
Parental organism
Canarypox virus
Transgene(s)
Haemagglutin HA gene from the equine influenza virus strains A/equi-2/Kentucky/94 (American strain) and A/equi-2/Newmarket/2/93 (European strain)
Treated organism
Horses
Indication(s)Active immunisation of horses of 4 months of age or older against equine influenza to reduce clinical signs and virus excretion after infection and against tetanus to prevent mortality.
Administration route(s)
Intramuscular
Type of authorisation
Centralised at european level
Legal frame
Council regulation (EEC) 2309/93 (full text in English or in French) and the environmental safety requirements laid down by European Directive 90/220/EEC, part C and the Royal Decree of 18/12/1998, article 22 (full text of the Decree in French - in Dutch)
Competent authority
EMEA/European Commission
Belgian advisory body
Belgian Biosafety Council
Date of the meeting of the Belgian Biosafety Council
4/02/2002
EMEA (CVMP) opinionpositive : abstract in english (link to Web site of EMEA)CVMP opinion date13/11/2002European Commission authorisation date6/03/2003European Commission authorisation numberEU/2/03/038/001-2-3-4European Commission decisionPharmacos linkEuropean Public Assessment Report (including Product information leaflet and Summary of product characteristics in French, in Dutch or in English)EPAR (link to Web site of EMEA)Notifications to Belgian authorities while in Research and Development stageB/BE/00/V15
ProteqFLU-Te
Application number
EMEA/V/C/074
Marketing authorisation holder
MERIAL, France
Name of the product
ProteqFLU-TeActive substances
Live recombinant canarypox viruses expressing the haemagglutin HA gene from the equine influenza virus strains A/equi-2/Kentucky/94 (USA representative) and A/equi-2/Newmarket/293 (European representative) + tetanus toxoid.
Parental organism
Canarypox virus
Transgene(s)
Haemagglutin HA gene from the equine influenza virus strains A/equi-2/Kentucky/94 (American strain) and A/equi-2/Newmarket/2/93 (European strain)
Treated organism
Horses
Indication(s)Active immunisation of horses of 4 months of age or older against equine influenza to reduce clinical signs and virus excretion after infection and against tetanus to prevent mortality.
Administration route(s)
Intramuscular
Type of authorisation
Centralised at european level
Legal frame
Council regulation (EEC) 2309/93 (full text in English or in French) and the environmental safety requirements laid down by European Directive 90/220/EEC, part C and the Royal Decree of 18/12/1998, article 22 (full text of the Decree in French - in Dutch)
Competent authority
EMEA/European Commission
Belgian advisory body
Belgian Biosafety Council
Date of the meeting of the Belgian Biosafety Council
4/02/2002
EMEA (CVMP) opinionpositive : abstract in english (link to Web site of EMEA)CVMP opinion date13/11/2002European Commission authorisation date6/03/2003European Commission authorisation numberEU/2/03/038/001-2-3-4European Commission decisionPharmacos linkEuropean Public Assessment Report (including Product information leaflet and Summary of product characteristics in French, in Dutch or in English)EPAR (link to Web site of EMEA)Notifications to Belgian authorities while in Research and Development stageB/BE/00/V15